Intrinsic value of Regeneron Pharmaceuticals - REGN

Previous Close

$387.25

  Intrinsic Value

$332.55

stock screener

  Rating & Target

hold

-14%

Previous close

$387.25

 
Intrinsic value

$332.55

 
Up/down potential

-14%

 
Rating

hold

We calculate the intrinsic value of REGN stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 0001), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 41.0

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2
   3
   4
   5
   6
   7
   8
   9
   10
   11
   12
   13
   14
   15
   16
   17
   18
   19
   20
   21
   22
   23
   24
   25
   26
   27
   28
   29
   30
   31

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  9.40
  8.96
  8.56
  8.21
  7.89
  7.60
  7.34
  7.10
  6.89
  6.70
  6.53
  6.38
  6.24
  6.12
  6.01
  5.91
  5.82
  5.73
  5.66
  5.59
  5.53
  5.48
  5.43
  5.39
  5.35
  5.32
  5.28
  5.26
  5.23
  5.21
Revenue, $m
  6,424
  7,000
  7,599
  8,223
  8,872
  9,546
  10,246
  10,974
  11,731
  12,517
  13,335
  14,186
  15,071
  15,994
  16,954
  17,956
  19,000
  20,089
  21,226
  22,414
  23,654
  24,951
  26,307
  27,724
  29,208
  30,761
  32,386
  34,088
  35,871
  37,739
Variable operating expenses, $m
  1,670
  1,820
  1,976
  2,138
  2,307
  2,482
  2,664
  2,853
  3,050
  3,254
  3,467
  3,688
  3,919
  4,158
  4,408
  4,668
  4,940
  5,223
  5,519
  5,828
  6,150
  6,487
  6,840
  7,208
  7,594
  7,998
  8,420
  8,863
  9,327
  9,812
Fixed operating expenses, $m
  2,368
  2,420
  2,473
  2,528
  2,583
  2,640
  2,698
  2,758
  2,818
  2,880
  2,944
  3,008
  3,075
  3,142
  3,211
  3,282
  3,354
  3,428
  3,503
  3,581
  3,659
  3,740
  3,822
  3,906
  3,992
  4,080
  4,170
  4,261
  4,355
  4,451
Total operating expenses, $m
  4,038
  4,240
  4,449
  4,666
  4,890
  5,122
  5,362
  5,611
  5,868
  6,134
  6,411
  6,696
  6,994
  7,300
  7,619
  7,950
  8,294
  8,651
  9,022
  9,409
  9,809
  10,227
  10,662
  11,114
  11,586
  12,078
  12,590
  13,124
  13,682
  14,263
Operating income, $m
  2,386
  2,760
  3,150
  3,557
  3,982
  4,424
  4,884
  5,363
  5,862
  6,382
  6,924
  7,489
  8,078
  8,693
  9,335
  10,005
  10,706
  11,438
  12,204
  13,006
  13,845
  14,724
  15,645
  16,610
  17,622
  18,683
  19,796
  20,964
  22,190
  23,476
EBITDA, $m
  2,545
  2,933
  3,338
  3,760
  4,201
  4,659
  5,137
  5,634
  6,152
  6,692
  7,254
  7,840
  8,451
  9,088
  9,754
  10,449
  11,175
  11,934
  12,728
  13,559
  14,429
  15,340
  16,295
  17,295
  18,343
  19,443
  20,596
  21,806
  23,076
  24,408
Interest expense (income), $m
  5
  38
  51
  65
  80
  95
  110
  127
  144
  161
  179
  198
  218
  239
  260
  282
  305
  329
  355
  381
  408
  437
  467
  498
  531
  565
  601
  638
  677
  718
  761
Earnings before tax, $m
  2,348
  2,708
  3,085
  3,478
  3,887
  4,313
  4,757
  5,220
  5,701
  6,203
  6,726
  7,271
  7,840
  8,433
  9,053
  9,700
  10,376
  11,083
  11,823
  12,597
  13,408
  14,257
  15,147
  16,079
  17,057
  18,082
  19,158
  20,287
  21,471
  22,715
Tax expense, $m
  634
  731
  833
  939
  1,049
  1,165
  1,284
  1,409
  1,539
  1,675
  1,816
  1,963
  2,117
  2,277
  2,444
  2,619
  2,802
  2,992
  3,192
  3,401
  3,620
  3,849
  4,090
  4,341
  4,605
  4,882
  5,173
  5,477
  5,797
  6,133
Net income, $m
  1,714
  1,977
  2,252
  2,539
  2,837
  3,149
  3,473
  3,810
  4,162
  4,528
  4,910
  5,308
  5,723
  6,156
  6,608
  7,081
  7,575
  8,091
  8,631
  9,196
  9,788
  10,408
  11,057
  11,738
  12,452
  13,200
  13,985
  14,809
  15,674
  16,582

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  9,284
  10,115
  10,982
  11,883
  12,820
  13,794
  14,807
  15,858
  16,952
  18,088
  19,270
  20,500
  21,780
  23,112
  24,500
  25,947
  27,456
  29,031
  30,674
  32,390
  34,183
  36,056
  38,015
  40,064
  42,208
  44,452
  46,801
  49,261
  51,837
  54,536
Adjusted assets (=assets-cash), $m
  9,284
  10,115
  10,982
  11,883
  12,820
  13,794
  14,807
  15,858
  16,952
  18,088
  19,270
  20,500
  21,780
  23,112
  24,500
  25,947
  27,456
  29,031
  30,674
  32,390
  34,183
  36,056
  38,015
  40,064
  42,208
  44,452
  46,801
  49,261
  51,837
  54,536
Revenue / Adjusted assets
  0.692
  0.692
  0.692
  0.692
  0.692
  0.692
  0.692
  0.692
  0.692
  0.692
  0.692
  0.692
  0.692
  0.692
  0.692
  0.692
  0.692
  0.692
  0.692
  0.692
  0.692
  0.692
  0.692
  0.692
  0.692
  0.692
  0.692
  0.692
  0.692
  0.692
Average production assets, $m
  2,428
  2,646
  2,873
  3,108
  3,353
  3,608
  3,873
  4,148
  4,434
  4,731
  5,041
  5,362
  5,697
  6,046
  6,409
  6,787
  7,182
  7,594
  8,024
  8,472
  8,941
  9,431
  9,944
  10,480
  11,041
  11,628
  12,242
  12,885
  13,559
  14,265
Working capital, $m
  1,959
  2,135
  2,318
  2,508
  2,706
  2,911
  3,125
  3,347
  3,578
  3,818
  4,067
  4,327
  4,597
  4,878
  5,171
  5,476
  5,795
  6,127
  6,474
  6,836
  7,215
  7,610
  8,024
  8,456
  8,908
  9,382
  9,878
  10,397
  10,941
  11,510
Total debt, $m
  952
  1,209
  1,477
  1,755
  2,045
  2,346
  2,658
  2,984
  3,321
  3,673
  4,038
  4,418
  4,813
  5,225
  5,654
  6,101
  6,567
  7,054
  7,561
  8,092
  8,646
  9,225
  9,830
  10,463
  11,126
  11,819
  12,545
  13,305
  14,101
  14,935
Total liabilities, $m
  2,869
  3,126
  3,393
  3,672
  3,961
  4,262
  4,575
  4,900
  5,238
  5,589
  5,954
  6,334
  6,730
  7,142
  7,571
  8,018
  8,484
  8,970
  9,478
  10,008
  10,562
  11,141
  11,747
  12,380
  13,042
  13,736
  14,461
  15,222
  16,018
  16,852
Total equity, $m
  6,415
  6,990
  7,588
  8,211
  8,859
  9,532
  10,231
  10,958
  11,714
  12,499
  13,316
  14,165
  15,050
  15,970
  16,930
  17,930
  18,972
  20,060
  21,196
  22,381
  23,620
  24,915
  26,269
  27,684
  29,166
  30,716
  32,339
  34,039
  35,819
  37,685
Total liabilities and equity, $m
  9,284
  10,116
  10,981
  11,883
  12,820
  13,794
  14,806
  15,858
  16,952
  18,088
  19,270
  20,499
  21,780
  23,112
  24,501
  25,948
  27,456
  29,030
  30,674
  32,389
  34,182
  36,056
  38,016
  40,064
  42,208
  44,452
  46,800
  49,261
  51,837
  54,537
Debt-to-equity ratio
  0.150
  0.170
  0.190
  0.210
  0.230
  0.250
  0.260
  0.270
  0.280
  0.290
  0.300
  0.310
  0.320
  0.330
  0.330
  0.340
  0.350
  0.350
  0.360
  0.360
  0.370
  0.370
  0.370
  0.380
  0.380
  0.380
  0.390
  0.390
  0.390
  0.400
Adjusted equity ratio
  0.691
  0.691
  0.691
  0.691
  0.691
  0.691
  0.691
  0.691
  0.691
  0.691
  0.691
  0.691
  0.691
  0.691
  0.691
  0.691
  0.691
  0.691
  0.691
  0.691
  0.691
  0.691
  0.691
  0.691
  0.691
  0.691
  0.691
  0.691
  0.691
  0.691

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  1,714
  1,977
  2,252
  2,539
  2,837
  3,149
  3,473
  3,810
  4,162
  4,528
  4,910
  5,308
  5,723
  6,156
  6,608
  7,081
  7,575
  8,091
  8,631
  9,196
  9,788
  10,408
  11,057
  11,738
  12,452
  13,200
  13,985
  14,809
  15,674
  16,582
Depreciation, amort., depletion, $m
  159
  173
  188
  203
  219
  236
  253
  271
  290
  309
  329
  350
  372
  395
  419
  444
  469
  496
  524
  554
  584
  616
  650
  685
  722
  760
  800
  842
  886
  932
Funds from operations, $m
  1,873
  2,150
  2,440
  2,742
  3,057
  3,384
  3,726
  4,081
  4,452
  4,837
  5,239
  5,658
  6,095
  6,551
  7,027
  7,524
  8,044
  8,587
  9,155
  9,750
  10,372
  11,024
  11,707
  12,423
  13,173
  13,960
  14,785
  15,651
  16,560
  17,514
Change in working capital, $m
  168
  176
  183
  190
  198
  206
  214
  222
  231
  240
  249
  260
  270
  281
  293
  305
  318
  332
  347
  362
  378
  395
  413
  432
  452
  474
  496
  519
  544
  570
Cash from operations, $m
  1,704
  1,975
  2,257
  2,552
  2,859
  3,179
  3,512
  3,859
  4,221
  4,598
  4,990
  5,399
  5,825
  6,270
  6,734
  7,219
  7,726
  8,255
  8,808
  9,388
  9,994
  10,629
  11,294
  11,990
  12,721
  13,486
  14,290
  15,132
  16,016
  16,944
Maintenance CAPEX, $m
  -145
  -159
  -173
  -188
  -203
  -219
  -236
  -253
  -271
  -290
  -309
  -329
  -350
  -372
  -395
  -419
  -444
  -469
  -496
  -524
  -554
  -584
  -616
  -650
  -685
  -722
  -760
  -800
  -842
  -886
New CAPEX, $m
  -207
  -218
  -227
  -236
  -245
  -255
  -265
  -275
  -286
  -297
  -309
  -322
  -335
  -349
  -363
  -378
  -395
  -412
  -430
  -449
  -469
  -490
  -512
  -536
  -561
  -587
  -614
  -643
  -674
  -706
Cash from investing activities, $m
  -352
  -377
  -400
  -424
  -448
  -474
  -501
  -528
  -557
  -587
  -618
  -651
  -685
  -721
  -758
  -797
  -839
  -881
  -926
  -973
  -1,023
  -1,074
  -1,128
  -1,186
  -1,246
  -1,309
  -1,374
  -1,443
  -1,516
  -1,592
Free cash flow, $m
  1,352
  1,598
  1,857
  2,128
  2,410
  2,705
  3,012
  3,331
  3,664
  4,010
  4,372
  4,748
  5,140
  5,549
  5,976
  6,422
  6,887
  7,374
  7,882
  8,414
  8,971
  9,554
  10,165
  10,804
  11,475
  12,178
  12,915
  13,689
  14,500
  15,352
Issuance/(repayment) of debt, $m
  248
  257
  268
  279
  290
  301
  313
  325
  338
  351
  365
  380
  395
  412
  429
  447
  466
  486
  508
  530
  554
  579
  605
  633
  662
  693
  726
  760
  796
  834
Issuance/(repurchase) of shares, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from financing (excl. dividends), $m  
  248
  257
  268
  279
  290
  301
  313
  325
  338
  351
  365
  380
  395
  412
  429
  447
  466
  486
  508
  530
  554
  579
  605
  633
  662
  693
  726
  760
  796
  834
Total cash flow (excl. dividends), $m
  1,600
  1,855
  2,125
  2,407
  2,700
  3,006
  3,324
  3,656
  4,002
  4,362
  4,737
  5,128
  5,535
  5,961
  6,405
  6,869
  7,353
  7,860
  8,390
  8,945
  9,525
  10,133
  10,770
  11,438
  12,137
  12,871
  13,641
  14,449
  15,296
  16,186
Retained Cash Flow (-), $m
  -545
  -575
  -599
  -623
  -648
  -673
  -699
  -727
  -755
  -785
  -817
  -850
  -884
  -921
  -959
  -1,000
  -1,043
  -1,088
  -1,135
  -1,186
  -1,239
  -1,295
  -1,354
  -1,416
  -1,481
  -1,550
  -1,623
  -1,700
  -1,780
  -1,865
Prev. year cash balance distribution, $m
  274
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
  1,329
  1,280
  1,526
  1,784
  2,052
  2,333
  2,625
  2,929
  3,246
  3,576
  3,920
  4,278
  4,651
  5,040
  5,446
  5,869
  6,311
  6,772
  7,255
  7,759
  8,286
  8,838
  9,416
  10,022
  10,656
  11,321
  12,018
  12,749
  13,516
  14,321
Discount rate, %
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
  1,275
  1,172
  1,328
  1,469
  1,591
  1,693
  1,773
  1,831
  1,865
  1,875
  1,862
  1,826
  1,768
  1,692
  1,599
  1,491
  1,373
  1,247
  1,117
  986
  857
  733
  617
  510
  415
  330
  258
  197
  148
  108
Current shareholders' claim on cash, %
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0

Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases. The Company's marketed products include EYLEA (aflibercept) Injection, Praluent (alirocumab) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use, Kevzara (sarilumab) Solution for Subcutaneous Injection and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion. As of December 31, 2016, the Company had 16 product candidates in clinical development, which consisted of a Trap-based clinical program and 15 fully human monoclonal antibody product candidates.

FINANCIAL RATIOS  of  Regeneron Pharmaceuticals (REGN)

Valuation Ratios
P/E Ratio 45.8
Price to Sales 8.4
Price to Book 9.2
Price to Tangible Book
Price to Cash Flow 27.9
Price to Free Cash Flow 42.7
Growth Rates
Sales Growth Rate 18.4%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate -24.5%
Cap. Spend. - 3 Yr. Gr. Rate 26.8%
Financial Strength
Quick Ratio 8
Current Ratio 0.1
LT Debt to Equity 7.9%
Total Debt to Equity 10.8%
Interest Coverage 267
Management Effectiveness
Return On Assets 14.3%
Ret/ On Assets - 3 Yr. Avg. 12.7%
Return On Total Capital 20%
Ret/ On T. Cap. - 3 Yr. Avg. 16.8%
Return On Equity 22.1%
Return On Equity - 3 Yr. Avg. 19.2%
Asset Turnover 0.8
Profitability Ratios
Gross Margin 93.8%
Gross Margin - 3 Yr. Avg. 92.3%
EBITDA Margin 29.6%
EBITDA Margin - 3 Yr. Avg. 30.4%
Operating Margin 27.4%
Oper. Margin - 3 Yr. Avg. 28.5%
Pre-Tax Margin 27.4%
Pre-Tax Margin - 3 Yr. Avg. 28.1%
Net Profit Margin 18.4%
Net Profit Margin - 3 Yr. Avg. 15.3%
Effective Tax Rate 32.6%
Eff/ Tax Rate - 3 Yr. Avg. 45.4%
Payout Ratio 0%

REGN stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the REGN stock intrinsic value calculation we used $5872.227 million for the last fiscal year's total revenue generated by Regeneron Pharmaceuticals. The default revenue input number comes from 0001 income statement of Regeneron Pharmaceuticals. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our REGN stock valuation model: a) initial revenue growth rate of 9.4% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for REGN is calculated based on our internal credit rating of Regeneron Pharmaceuticals, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Regeneron Pharmaceuticals.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of REGN stock the variable cost ratio is equal to 26%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $2317 million in the base year in the intrinsic value calculation for REGN stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 5.4% for Regeneron Pharmaceuticals.

Corporate tax rate of 27% is the nominal tax rate for Regeneron Pharmaceuticals. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the REGN stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for REGN are equal to 37.8%.

Life of production assets of 15.3 years is the average useful life of capital assets used in Regeneron Pharmaceuticals operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for REGN is equal to 30.5%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $6144.078 million for Regeneron Pharmaceuticals - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 105.95 million for Regeneron Pharmaceuticals is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Regeneron Pharmaceuticals at the current share price and the inputted number of shares is $41.0 billion.

RELATED COMPANIES Price Int.Val. Rating
AMGN Amgen 205.10 130.16  sell
OPHT Ophthotech 2.46 0.26  str.sell

COMPANY NEWS

▶ The 7 Best Biotech Stocks for Investors Who Hate Risk   [Sep-20-18 03:12PM  Kiplinger]
▶ 5 Stocks Primed To Fall Lower In The Coming Days   [Sep-19-18 05:05PM  Benzinga]
▶ Bluebird Bio Stock May Have Upside of at Least 60 Percent   [Sep-12-18 06:00PM  InvestorPlace]
▶ Arrowhead Stock Is Not Done Rallying After Its 38% Jump   [Sep-07-18 02:10PM  InvestorPlace]
▶ Sizzling Stocks: 4 trades   [06:30PM  CNBC Videos]
▶ 3 Stocks That May Lead a Massive Biotech Breakout   [Aug-29-18 02:00PM  Investopedia]
▶ Play The Future of Gene Therapy With These 5 Biotech Stocks   [Aug-27-18 12:14PM  InvestorPlace]
▶ 5 Low-Cost Biotech Stocks With High Levels of Growth   [Aug-21-18 10:41AM  InvestorPlace]
▶ Know This Sell Signal: When Stock Leaders Stage Big Downside Reversals   [Aug-13-18 05:00PM  Investor's Business Daily]
▶ Carl Icahn Fires Shots at Express Scripts   [Aug-09-18 10:25PM  Motley Fool]
▶ Why this company's Durham outpost may benefit from $100M investment   [Aug-07-18 11:30AM  American City Business Journals]
▶ Can These Biotech Companies Catch Novartis, Gilead In CAR-T?   [Aug-06-18 04:15PM  Investor's Business Daily]
▶ Company News For Aug 3, 2018   [Aug-03-18 09:33AM  Zacks]
▶ Can Regeneron Stock Hit $400 For The First Time This Year?   [Aug-02-18 04:13PM  Investor's Business Daily]
▶ Dow Jones Falls On Trade War Fears; Tesla Stock Buoys Nasdaq   [12:05PM  Investor's Business Daily]
▶ Regeneron: 2Q Earnings Snapshot   [06:53AM  Associated Press]
▶ Regeneron Pharmaceuticals Earnings Outlook   [Aug-01-18 03:46PM  Benzinga]
▶ Why Sanofi Stock Should Run Higher Despite Mixed Earnings   [Jul-31-18 12:05PM  InvestorPlace]
▶ 3 Hot Biotech Stocks With More Gains Ahead   [06:00AM  Investopedia]
▶ GlaxoSmithKline Is More Than Just a 5% Dividend Income Play   [Jul-17-18 12:33PM  InvestorPlace]
▶ 3 Top Biotech Stocks to Buy in July   [Jul-06-18 08:01PM  Motley Fool]
▶ Upside 'Substantial' As Regeneron Ups Price On Blockbuster Hopeful   [Jul-02-18 04:38PM  Investor's Business Daily]
▶ Regeneron, McKesson, AmerisourceBergen, FedEx & Hilton   [Jun-28-18 01:57PM  CNBC Videos]
▶ Regeneron: 'On the Cusp' of Big Sales Growth   [Jun-27-18 11:09AM  Barrons.com]

CONTACT US       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.